BeiGene, Ltd. (NASDAQ:BGNE) Insider Xiaodong Wang Sells 41,760 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNEGet Free Report) insider Xiaodong Wang sold 41,760 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $186.90, for a total transaction of $7,804,944.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Xiaodong Wang also recently made the following trade(s):

  • On Tuesday, November 26th, Xiaodong Wang sold 40,468 shares of BeiGene stock. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80.

BeiGene Stock Performance

Shares of BeiGene stock opened at $180.27 on Friday. The business has a fifty day simple moving average of $208.56 and a 200-day simple moving average of $186.47. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock has a market cap of $17.56 billion, a PE ratio of -21.88 and a beta of 0.57. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $248.16.

BeiGene (NASDAQ:BGNEGet Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 earnings per share. On average, sell-side analysts anticipate that BeiGene, Ltd. will post -5.64 EPS for the current fiscal year.

Institutional Trading of BeiGene

Institutional investors and hedge funds have recently modified their holdings of the company. Blue Trust Inc. grew its stake in shares of BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares during the last quarter. Raymond James & Associates increased its holdings in shares of BeiGene by 0.4% during the 2nd quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock worth $3,035,000 after purchasing an additional 76 shares during the period. Truist Financial Corp raised its position in shares of BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock valued at $217,000 after buying an additional 140 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in BeiGene during the third quarter valued at about $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in BeiGene by 0.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock valued at $21,978,000 after acquiring an additional 266 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on BGNE shares. JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $300.00 price objective on shares of BeiGene in a report on Tuesday, December 3rd. TD Cowen raised their price objective on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price target on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com lowered shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.69.

Read Our Latest Research Report on BGNE

About BeiGene

(Get Free Report)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.

Featured Articles

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.